scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1021016376 |
P356 | DOI | 10.1245/S10434-014-3767-6 |
P8608 | Fatcat ID | release_umvmngze5zhrbblyxl2intiice |
P698 | PubMed publication ID | 24841346 |
P50 | author | Betro T Sadek | Q39032327 |
P2093 | author name string | Pauline T Truong | |
Alphonse G Taghian | |||
Rita Abi Raad | |||
Mina Shenouda | |||
Cheryl S Alexander | |||
David J Peterson | |||
Bradley Wiksyk | |||
P2860 | cites work | High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 |
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
Molecular portraits of human breast tumours | Q28032461 | ||
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials | Q29031162 | ||
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
Younger age as a prognostic indicator in breast cancer: a cohort study | Q34003908 | ||
The impact of age on outcome in early-stage breast cancer | Q34584831 | ||
Epidermal growth factor family receptors and inhibitors: radiation response modulators | Q35042083 | ||
Triple-negative breast cancer is not a contraindication for breast conservation | Q35111687 | ||
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy | Q35289587 | ||
Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy | Q37355667 | ||
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer | Q37467023 | ||
Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? | Q37586016 | ||
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype | Q37965397 | ||
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial | Q39404724 | ||
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review | Q40442632 | ||
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. | Q42434873 | ||
Breast cancer subtypes and the risk of local and regional relapse. | Q42468027 | ||
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer | Q43250044 | ||
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project random | Q45081463 | ||
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial | Q46736552 | ||
Amplification of a novel v-erbB-related gene in a human mammary carcinoma | Q48375434 | ||
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. | Q53890280 | ||
Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. | Q54563619 | ||
P433 | issue | 11 | |
P921 | main subject | trastuzumab | Q412616 |
P304 | page(s) | 3490-3496 | |
P577 | publication date | 2014-05-20 | |
P1433 | published in | Annals of Surgical Oncology | Q2853069 |
P1476 | title | Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer | |
P478 | volume | 21 |
Q36908374 | Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer |
Q90049544 | Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis |
Q36308052 | Her2 positivity and race predict higher mastectomy rates: a SEER database analysis |
Q40382522 | Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy |
Q50045468 | Molecular Subtypes and Local-Regional Control of Breast Cancer. |
Q47939862 | Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience |
Q36754437 | Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice |
Q54298427 | The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy. |
Search more.